相关实验视频

Updated: May 6, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

揭示FTO多态度在预测免疫检查点抑制剂反应中的作用:一项回顾性研究

Wenhui Liu¹, Chenlin Xiao¹, Jianquan Luo¹

¹Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, PR China; Institute of Clinical Pharmacy, Central South University, Changsha, PR China.

International immunopharmacology

|April 26, 2024

概括

脂肪质量和与肥胖相关的蛋白质 (FTO) 基因变异可能预测癌症患者对免疫检查点抑制剂 (ICI) 的反应. 特定的FTO多态性与改善无进展生存率和整体生存率有关,可能作为免疫治疗有效性的生物标志物.

科学领域:

药物基因组学药物基因组学
癌症免疫疗法癌症免疫疗法
分子生物学分子生物学

背景情况:

识别受益于免疫检查点抑制剂 (ICI) 的患者对于有效的癌症免疫治疗至关重要.
脂肪质量和与肥胖相关的蛋白质 (FTO) 基因在治疗结果中的作用需要进一步调查.

研究的目的:

探索FTO基因多态化与接受ICI的患者治疗结果之间的关联.
为了确定潜在的遗传生物标志物来预测ICI疗效.

主要方法:

对371名用ICI治疗的癌症患者进行了回顾性分析.
使用Sequenome MassARRAY对7种FTO基因变异进行基因定型.
对FTO基因型与无进展生存率 (PFS),总生存率 (OS) 和免疫相关不良事件 (irAEs) 的关联分析.

主要成果:

特定的FTO基因型 (rs11075995 AT/TT,rs12596638 GG,rs12600192 CC) 与改善的PFS和OS有关.
rs12600192 CC基因型与严重的irrAEs风险降低相关.
考克斯回归确定了FTO多态和生存结果之间的独立关联.

结论:

在固体瘤中,FTO基因多态是ICI治疗结果的潜在预测生物标志物.
这些发现可能有助于个性化免疫治疗策略.
需要进一步的研究来验证FTO作为预测标记.

关键词:

反PD-1 封锁系统的封锁免疫检查点抑制剂免疫检查点抑制剂与免疫相关的不良事件.免疫治疗是一种免疫疗法.治疗生物标志物治疗生物标志物

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...